Reported about 23 hours ago
This article evaluates Merck & Co., Inc. (MRK) as a strong contender among large-cap value stocks in the context of an impending recession. Analysts note that while MRK's flagship drug, KEYTRUDA, supports its market position, recent inventory issues have caused short-term concerns. Despite challenges, some experts believe MRK's valuation may be too pessimistic, highlighting its growth potential. However, the article suggests that certain AI stocks may offer even higher returns, positioning MRK fifth in the ranking of recommended stocks.
Source: YAHOO